Harpoon Therapeutics Inc at HC Wainwright Immune Cell Engager Virtual Conference Transcript

Aug 17, 2023 / 02:30PM GMT
Swayampakula Ramakanth - H.C. Wainwright & Co., LLC, LLC - Analyst

Greetings and thanks for joining us to have a conversation with Julie Eastland, CEO; and Luke Walker, CMO of Harpoon Therapeutics. Harpoon is developing next-generation tumor activated T cell engagers and has developed three different platforms: TriTAC, ProTriTAC, and TriTAC-XR. The company also has three drugs in clinical development and several preclinical molecules. To discuss the company's development strategy in '23 and beyond, I welcome Julie and Luke to this fireside chat.

Good morning, Julie and Luke. Thank you for joining us and really appreciate you accepting our invitation and to talk to our audience this morning.

Julie Eastland - Harpoon Therapeutics, Inc. - President and CEO

Thank you, RK. Actually, thanks for having us. We appreciate it.

Questions and Answers:

Swayampakula Ramakanth - H.C. Wainwright & Co., LLC, LLC - Analyst

So just to get started, Julie, for people who are new to Harpoon, could you please give us
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot